Novartis AG (NVS)
After hours:
| Previous Close | 113.77 |
| Open | 112.88 |
| Bid | 113.00 x 800 |
| Ask | 116.23 x 900 |
| Day's Range | 112.80 - 114.02 |
| 52 Week Range | 92.19 - 120.92 |
| Volume | |
| Avg. Volume | 1,180,553 |
| Market Cap | 232.218B |
| Beta (5Y Monthly) | 0.50 |
| PE Ratio (TTM) | 23.30 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.78 (3.31%) |
| Ex-Dividend Date | Mar 07, 2024 |
| 1y Target Est | N/A |
- GlobeNewswire
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy1,2Kisqali® (ribociclib) significantly reduced the risk of recurrence by 25% vs. endocrine therapy (ET) alone; consistent benefit and a well-tolerated safety profile seen across all subgroups in pivotal Phase III NATALEE trial, including patients with node-negative disease3-6La
- GlobeNewswire
Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease1Results remain consistent across secondary endpoints, including distant disease-free survival, with a trend for improved overall survival*1Safety is in line with previously reported results with generally low-grade symptomatic adverse events, reinforcing well-tolerated profile1People diagnosed with stage II or II
- GlobeNewswire
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager to receive upfront consideration of $15 million and is eligible to receive up to $305 million in potential associated milestone payments and royaltiesLEXINGTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Novartis AG (NYSE: NVS) has agreed to license a novel capsid generated from Voyager’s TRACER™ capsid discovery platform for use in a gene therapy program
